Top 10 Companies in the South Korea Kawasaki Disease Market | Competitive Landscape 2026

Top 10 Companies in the South Korea Kawasaki Disease Market

The South Korea Kawasaki Disease(KD) market is a convergence of high-tech, advanced plasma fractionation, state-of-the-art paediatric clinical protocols, and a robust national health insurance infrastructure. The market is largely driven by the availability of high purity intravenous immunoglobulin (IVIG) and rapid diagnostic integration required to prevent long-term cardiac complications for a systemic vasculitis that requires immediate intervention.

South Korea Kawasaki Disease Market Overview

According to 6Wresearch, the South Korea Kawasaki Disease market is projected to grow, due to the advanced healthcare infrastructure, and early detection initiatives. South Korea’s medical community have an advanced protocols in the world for treating KD in children. The market is supported by the National Health Insurance (NHI) system, which guarantees access to costly biological treatments, thus ensuring that paediatric patients receive equal care, regardless of financial status. Moreover, the proximity of university-affiliated hospitals and domestic biopharmaceutical companies, makes South Korea a global leader in clinical research for Kawasaki disease.

Competitive Landscape

The competitive landscape of the South Korea Kawasaki Disease industry is intense with companies that have expertise in plasma-derived therapeutics, and complex injectables. These brands comply with strict GMP standards, and have developed long-term partnerships with tertiary paediatric medical centres, to ensure the continuous supply of life-saving immunoglobulins and anti-inflammatory therapies.

Below is a list of leading players operating in the South Korea Kawasaki Disease Market:

1. GC Biopharma

GC Biopharma is a primary supplier of high-purity IVIG products critical for the acute-phase treatment of Kawasaki disease.

2. SK Plasma

Specializes in blood-derived biologicals; its "Liv-Gamma" line is widely utilized in clinical settings for the prevention of coronary artery complications in KD patients.

3. JW Pharmaceutical

Provides a wide range of essential hospital-grade fluids, antibiotics, and anti-inflammatory agents that support the management of paediatric vasculitis.

4. Hanmi Pharmaceutical

A major force in R&D, focusing on advanced drug delivery and high-quality medications that address the inflammation management needs of patients.

5. Daewoong Pharmaceutical

Supplies essential therapeutic solutions and maintains an extensive distribution network across South Korean paediatric clinics and hospitals.

6. Yuhan Corporation

Known for its strong presence in ethical drug distribution, providing stable supplies of anti-inflammatory medications necessary for Kawasaki patients.

7. Boryung

An established player in the cardiovascular and metabolic drug space, contributing to the supportive care and secondary management of paediatric vasculitis cases.

8. Kwang Dong Pharmaceutical

A trusted manufacturer providing a diverse portfolio of clinical-grade medications utilized in emergency care and long-term paediatric inflammatory support.

9. Il-Yang Pharmaceutical

Focused on the development of novel therapeutics and essential medicines, ensuring the availability of treatments for acute and chronic conditions in children.

10. Samjin Pharmaceutical

Maintains a robust portfolio of anti-inflammatory and circulatory health products that serve as adjunct therapies in the broader care of Kawasaki disease patients.

Top 10 Companies in the South Korea Kawasaki Disease Market: FAQs